Shay Shemesh
Fondateur chez NUVECTIS PHARMA, INC.
Fortune : 10 M $ au 30/04/2024
Postes actifs de Shay Shemesh
Sociétés | Poste | Début | Fin |
---|---|---|---|
NUVECTIS PHARMA, INC. | Directeur des opérations | 27/07/2020 | - |
Fondateur | 27/07/2020 | - | |
Corporate Officer/Principal | 27/07/2020 | - |
Historique de carrière de Shay Shemesh
Anciens postes connus de Shay Shemesh
Sociétés | Poste | Début | Fin |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2015 | 01/01/2020 |
Conseiller Juridique Général | 01/01/2015 | 01/01/2020 | |
KERYX BIOPHARMACEUTICALS | Directeur Technique/Scientifique/R&D | - | - |
Formation de Shay Shemesh
Bar-Ilan University | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 4 |
Israël | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Chief Operating Officer | 1 |
Founder | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
NUVECTIS PHARMA, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Shay Shemesh
- Expérience